85%Confidence
0Views
FDASource
2026-03-17Date
Summary
Cipla's Nilotinib Capsules recall due to stability failures indicates potential supply chain disruptions for this cancer medication, which could affect patient access and Cipla's reputation in the US market. The Class III designation suggests lower immediate health risk but highlights quality control issues at the manufacturing site in India.
Actionable: Monitor Cipla's manufacturing compliance and consider alternative suppliers for Nilotinib to mitigate supply risks.
AI Confidence: 85%
Data Points
firmCipla USA, Inc.
classificationClass III
statusOngoing
distributionU.S.A. Nationwide
productNilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, Manufactured for: Cipla USA, Inc
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now